Kata® puts an end to inefficient inhalation therapy

The start of the first purely digital therapy support for chronic respiratory diseases

Garching bei München, 08.04.2019 – The therapy aid Kata® from the Munich start-up VisionHealth has been accompanying patients with chronic respiratory diseases since today. Using state-of-the-art technologies such as artificial intelligence (AI), it ensures more effective inhalation medication intake and offers the ideal therapy support between visits to the doctor with a wide range of functions relating to the disease. It is the first comprehensive, purely digital treatment support that is now available free of charge in the form of an app in the Apple App Store and Google Play Store.

KI trains patients to use their inhaled medications effectively

The unique thing about Kata® is that the app provides feedback on the inhalation maneuvers of the patients without the need for a medical expert to provide on-site or remote diagnosis support in this situation. This works only with the patient’s smartphone, without the need for additional devices. VisionHealth uses state-of-the-art technologies and has developed a special algorithm for this purpose. In addition to artificial intelligence, augmented reality elements are also used.

In addition to automatic inhalation training, Kata® also offers a reminder function and encouragement for adherence to therapy, as well as information on illness, weather, and pollen count. In addition, the diary function and control tests provide an overview of the course of the most important disease values. In addition, patients receive personal support from experts via email or telephone.

Not being able to breathe is a nightmare – but a regular reality for millions of people.

According to the World Health Organization (WHO), 600 million people worldwide suffer from chronic respiratory diseases and 3.5 million people die every year as a result. Founder and CEO Dr. Sabine Häußermann emphasizes: “All these patients have to struggle with a significant problem. The success of their treatment depends largely on the correct handling of their inhalers. According to current studies, however, up to 90% of patients make at least one mistake when using their inhalers. Therefore, we now offer a solution that can actually improve dose accuracy and adherence management”.

To achieve this, VisionHealth is developing digital therapy support from the outset with the support of experts who deal with the problem on a daily basis: Patients and doctors. “When I heard about VisionHealth and Kata®, I immediately became curious. Frank Hennemann, a patient with alpha-1-antitrypsin deficiency and a passionate motorcyclist, has been involved in the development of VisionHealth’s therapy aid as a member of the advisory board. “Since I tried the app, I don’t want to miss it anymore. I have a much better quality of life now than I did in the past”.

With vision into the future

Today, the solution already works for the most common form of inhalation spray, the so-called MDI (Metered Dose Inhaler). Managing Director Philipp Kroneberg makes it clear, however, that the enthusiasts at VisionHealth do not consider all potential to be exhausted: “We will further develop our technology for all device types so that every patient can use Kata® regardless of his prescribed medication. In the long term, we will also create a comprehensive platform to support patients in all aspects of their therapy between visits to the doctor. We will create a point of contact for patients with each other and with their points of contact in the healthcare system. In order to make everyday life easier for chronically ill patients, we involve a wide variety of partners and strive for support from health insurance companies.”

However, Kata not only helps individual patients but also contributes to the treatment therapy of the future. The (anonymous) insights about the application and at the same time the benefit of the therapies will help future patients to a more effective and better application. Basic research can evaluate these results and incorporate them into new developments. Existing therapies can also be re-evaluated. In the long term, Kata will even be able to detect signs of exacerbations. Early intervention can then prevent or at least alleviate hospital stays.